Novel agents for the treatment of childhood leukemia: an update

References

• FarberSDiamondLKMercerRDTemporary remissions in acute leukemia in children produced by folic acid antagonist,4-aminopteroylglutamic acidN Engl J Med19482382378779318860765
   PubMed Web of Science ®Google Scholar
• FreiEFreireichEJGehanEStudies of sequential and combination antimetabolite therapy in acute leukemia: 6-mercaptopurine and methotrexateBlood196118431454
   Web of Science ®Google Scholar
• PinkelDFive-year follow-up of “total therapy” of childhood lymphocytic leukemiaJAMA19712166486525279904
   PubMed Web of Science ®Google Scholar
• SullivanMPChenTDymentPGHvizdalaESteuberCPEquivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia: a pediatric oncology group studyBlood19826049489586956376
   PubMedGoogle Scholar
• PullenJBoyettJShusterJExtended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group studyJ Clin Oncol19931158398498487048
   PubMedGoogle Scholar
• JonesBFreemanAIShusterJJLower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemiaMed Pediatr Oncol19911942692752056971
   PubMedGoogle Scholar
• KrynetskiEYSchuetzJDGalpinAJPuiCHRellingMVEvansWEA single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferaseProc Natl Acad Sci U S A19959249499537862671
   PubMed Web of Science ®Google Scholar
• MurphySLXuJKochanekKDDeaths: Final Data for 2010 National Vital Statistics Reports 61(4)Hyattsville, MDNational Center for Health Statistics2013
   Google Scholar
• SallanSEHitchcock-BryanSGelberRCassadyJRFreiE3rdNathanDGInfluence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemiaCancer Res19834311560156076352020
   PubMed Web of Science ®Google Scholar
• BrownPHungerSPSmithFOCarrollWLReamanGHNovel targeted drug therapies for the treatment of childhood acute leukemiaExpert Rev Hematol20092914520126514
   PubMedGoogle Scholar
• RubnitzJEInabaHLeungWHDefinition of cure in childhood acute myeloid leukemiaCancer2014120162490249624798038
   PubMedGoogle Scholar
• RubnitzJEHow I treat pediatric acute myeloid leukemiaBlood2012119255980598822566607
   PubMed Web of Science ®Google Scholar
• RitterJCreutzigUZimmermanMSpecific role of idarubicin during induction therapy of childhood acute myeloblastic leukemia acute leukemia VISer Haematol Blood Transfus199738396399
   Google Scholar
• FleischhackGHasanCGrafNMannGBodeUIDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trialBr J Haematol199810236476559722289
   PubMedGoogle Scholar
• HuangMYu-ChenYShu-RongCUse of all-trans retinoic acid in the treatment of acute promyelocytic leukemiaBlood1988725675783165295
   PubMed Web of Science ®Google Scholar
• TallmanMSAltmanJKHow I treat acute promyelocytic leukemiaBlood2009114255126513519797519
   PubMed Web of Science ®Google Scholar
• EvansWERellingMVRodmanJHCromWRBoyettJMPuiCHConventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemiaN Engl J Med199833884995059468466
   PubMedGoogle Scholar
• SchultzKRImproved early event-free survival with imatinib in Philadelphia chromosome–positive acute lymphoblastic leukemia: a Children’s Oncology Group StudyJ Clin Oncol200927315175518119805687
   PubMed Web of Science ®Google Scholar
• SteinbergMDasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemiaClin Ther200729112289230818158072
   PubMed Web of Science ®Google Scholar
• SmallDTargeting FLT3 for treatment of leukemiaSemin Hematol2008453 suppl 2S17S2118760705
   PubMed Web of Science ®Google Scholar
• FathiALevisMFLT3 inhibitors: a story of the old and the newCurr Opin Hematol2011182717621245757
   PubMed Web of Science ®Google Scholar
• BrownPLevisMMcIntyreEGriesemerMSmallDCombinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent mannerLeukemia20062081368137616761017
   PubMedGoogle Scholar
• Al-kaliAGandhiVAyoubiMKeatingMRavandiFForodesine: review of preclinical and clinical dataFuture Oncol2010681211121720799866
   PubMedGoogle Scholar
• BurkeMJLambaJKPoundsSA therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia (ALL)Am J Hematol201489988989524891274
   PubMed Web of Science ®Google Scholar
• AndradeAFBorgesKSCastro-GameroAMZebularine induces chemosensitization to methotrexate and efficiently decreases AhR gene methylation in childhood acute lymphoblastic leukemia cellsAnticancer Drugs2014251728124052107
   PubMed Web of Science ®Google Scholar
• LeoneGSicaSVosoMTRutellaSPaganoLTreatment of acute leukaemias with monoclonal antibodies: current status and future prospectsCardiovasc Hematol Agents Med Chem200641335216529548
   PubMedGoogle Scholar
• BhojwaniDPuiCHRelapsed childhood acute lymphoblastic leukaemiaLancet Oncol2013146e205e21723639321
   PubMed Web of Science ®Google Scholar
• DyerMJKelseySMMackayHJIn vivo ‘purging’ of residual disease in CLL with Campath-1HBr J Haematol19979736696729207420
   PubMed Web of Science ®Google Scholar
• RaetzEACairoMSBorowitzMJRe-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): phase II results from Children’s Oncology Group (COG) study ADVL04P2Pediatr Blood Cancer20156271171117525732247
   PubMed Web of Science ®Google Scholar
• LinenbergerMLCD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistanceLeukemia200519217618215592433
   PubMed Web of Science ®Google Scholar
• ThomasXProfile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemiaBlood Lymphatic Cancer2014418
   Google Scholar
• AlbertsonTMSandalicLBaitengZA novel Anti-CD19 antibody drug conjugateCancer Res20147419DDT0104
   Google Scholar
• ShiHSunMLiuLWangZChimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospectsMol Cancer20141321925241075
   PubMed Web of Science ®Google Scholar
• MausMVJuneCHMaking better chimeric antigen receptors for adoptive T-cell therapyClin Cancer Res20162281875188427084741
   PubMed Web of Science ®Google Scholar
• HoffmanLMGoreLBlinatumomab, a bi-specific anti-CD19/CD3 BiTE(®) antibody for the treatment of acute lymphoblastic leukemia: perspectives and current pediatric applicationsFront Oncol201446324744989
   PubMedGoogle Scholar
• ToppMSGokbugetNSteinASSafety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 studyLancet Oncol2015161576625524800
   PubMed Web of Science ®Google Scholar
• DaiHWangYLuXChimeric antigen receptors modified T-cells for cancer therapyJ Natl Cancer Inst20161087djv43926819347
   PubMedGoogle Scholar
• SrivatsanSPatelJMBozemanENAllogeneic tumor cell vaccinesHum Vaccin Immunother2014101526324064957
   PubMed Web of Science ®Google Scholar
• ShahNNDaveHWayneASImmunotherapy for pediatric leukemiaFront Oncol2013316623847759
   PubMedGoogle Scholar
• BernemanZNVeldeAVAnguilleSPrevention of relapse in acute myeloid leukemia by dendritic cell vaccination: report on a Phase II Study with 29 patientsBlood2013122236
   Google Scholar
• OriuchiNHiguchiTHanaokaHIidaYEndoKCurrent status of cancer therapy with radiolabeled monoclonal antibodyAnn Nucl Med200519535536516164191
   PubMedGoogle Scholar
• WisemanGAWhiteCAWitzigTERadioimmunotherapy of relapsed non-Hodgkin’s lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibodyClin Cancer Res199953281s3286s10541376
   PubMed Web of Science ®Google Scholar
• RaoAVAkabaniGRizzieriDARadioimmunotherapy for non-Hodgkin’s lymphomaClin Med Res20053315716516160070
   PubMedGoogle Scholar
• BerntKMHungerSPCurrent concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaFront Oncol201445424724051
   PubMedGoogle Scholar
• YeQJiangJGuangunZSmall molecule activation of NOTCH signaling inhibits acute myeloid leukemiaSci Rep201662651027211848
   PubMedGoogle Scholar
• BorkinDPollockJKempinskaKProperty focused structure-based optimization of small molecule inhibitors of the protein-protein interaction between menin and mixed lineage leukemia (MLL)J Med Chem201659389291326744767
   PubMedGoogle Scholar
• KimBHYinCHGuoQA small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cellsMol Cancer Ther2008792672268018790749
   PubMed Web of Science ®Google Scholar
• CoffeyRTShiYLongMJMarrMTHedstromLUbiquilin mediated small molecule inhibition of mammalian target of rapamycin complex 1 (mTORC1) signalingJ Biol Chem2016291105221523326740621
   PubMedGoogle Scholar
• MartelliAMYakernMNTabelliniGPhosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemiaLeukemia200620691192816642045
   PubMed Web of Science ®Google Scholar
• FullmerAO’BrienSKantarjianHJabbourENovel therapies for relapsed acute lymphoblastic leukemiaCurr Hematol Malig Rep20094314815620425428
   PubMedGoogle Scholar
• DeAngeloDJNelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphomaHematol Oncol Clin North Am20092351121113519825456
   PubMedGoogle Scholar
• FernandezCAStewartEPanettaJCSuccessful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginaseCancer Chemother Pharmacol20147361307131324771103
   PubMedGoogle Scholar
• DavisTFaragSSTreating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristineInt J Nanomedicine201383479348824072970
   PubMed Web of Science ®Google Scholar
• GlantzMJLaFoletteSJaeckleKARandomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitisJ Clin Oncol199917103110311610506606
   PubMed Web of Science ®Google Scholar
• SedkiMVannierJPLevergerGLiposomal daunorubicin (Daunoxome) and polyethylated glycol conjugated asparaginase (PEG-ASPA) in children with relapsed and refractory acute lymphoblastic leukemia treated on compassionate basisJ Egypt Natl Canc Inst2008201556219847282
   PubMedGoogle Scholar
• KaspersGJZimmermannMReinhardtDImproved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study GroupJ Clin Oncol201331559960723319696
   PubMed Web of Science ®Google Scholar
• RafiyathSMRasulMLeeBWeiGLambaGLiuDComparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysisExp Hematol Oncol2012111023210520
   PubMedGoogle Scholar
• KurtzbergJPolyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children’s Oncology Group StudyJ Pediatr Hematol Oncol201133861061622042277
   PubMed Web of Science ®Google Scholar
• SabnisNBowmanWPLackoAGLipoprotein based drug delivery: potential for pediatric cancer applicationsWorld J Pharmacol201542172179
   Google Scholar
• VeldersMPProspects for immunotherapy of acute lymphoblastic leukemiaNature2001155701706
   Google Scholar
• PreudhommeCGuilhotJNicoliniFEImatinib plus peginterferon alfa-2a in chronic myeloid leukemiaN Engl J Med2010363262511252121175313
   PubMed Web of Science ®Google Scholar
• ChangYJHuangXJDonor lymphocyte infusions for relapse after allogeneic transplantation: when, if and for whom?Blood Rev2013271556223261066
   PubMed Web of Science ®Google Scholar
• ThomasAHow can we improve on the already impressive results in pediatric ALL?Hematology Am Soc Hematol Educ Program20152015141441926637751
   PubMedGoogle Scholar